Parkinson’s disease, treatment choice and survival over time
Objectives: We compared Monoamine oxidase B (MAO-B) – and dopamine agonist (DA) monotherapy patients with respect to survival, considering gender, age, first prescriber’s specialty and relevant co-morbidity, and compared their specialist health care contacts and hospitalizations. Methods: With data...
Main Authors: | I.F. Tvete, M. Klemp |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2022-01-01
|
Series: | Clinical Parkinsonism & Related Disorders |
Online Access: | http://www.sciencedirect.com/science/article/pii/S259011252200007X |
Similar Items
-
Off-time Treatment Options for Parkinson’s Disease
by: Margherita Fabbri, et al.
Published: (2023-01-01) -
Patients’ Preferences for Adjunctive Parkinson’s Disease Treatments: A Discrete-Choice Experiment
by: Serbin M, et al.
Published: (2023-09-01) -
Dopamine affects short-term memory corruption over time in Parkinson's disease
by: Fallon, SJ, et al.
Published: (2019) -
Correction to: Off-time Treatment Options for Parkinson’s Disease
by: Margherita Fabbri, et al.
Published: (2023-02-01) -
Association between serum lipid levels over time and risk of Parkinson’s disease
by: Kyungduk Hurh, et al.
Published: (2022-12-01)